Walvax BioTech (300142) — Capital Reinvestment Ratio

Latest as of June 2025: 0.26x

Walvax BioTech (300142) has a Capital Reinvestment Ratio of 0.26x as of June 2025, meaning it reinvests 0% of its operating cash flow (CN¥278.33 Million) in capital expenditures (CN¥71.03 Million). Check 300142 tangible net assets ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.26x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥278.33 Million
CNY

Capital Expenditures

CN¥71.03 Million
CNY

Data as of

Jun 2025
Most recent filing

Walvax BioTech Capital Reinvestment Ratio (2007–2025)

This chart tracks Walvax BioTech's Capital Reinvestment Ratio across 12 annual periods. For the full cash flow conversion analysis, see 300142 cash generation efficiency.

Annual Capital Reinvestment Ratio for Walvax BioTech (2007–2025)

Year-by-year Capital Reinvestment Ratio for Walvax BioTech from 2007 to 2025. See free cash flow generation of Walvax BioTech to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 1.03x CN¥494.37 Million CN¥509.54 Million ▲ +94.2%
2024 0.53x CN¥1.04 Billion CN¥550.03 Million ▼ -36.4%
2023 0.83x CN¥1.13 Billion CN¥945.52 Million ▼ -8.2%
2022 0.91x CN¥1.20 Billion CN¥1.09 Billion ▼ -42.0%
2021 1.56x CN¥705.28 Million CN¥1.10 Billion ▼ -56.1%
2020 3.57x CN¥114.19 Million CN¥407.13 Million ▼ -37.2%
2019 5.67x CN¥62.02 Million CN¥351.82 Million ▲ +24.9%
2012 4.54x CN¥78.38 Million CN¥355.87 Million ▲ +111.4%
2011 2.15x CN¥91.98 Million CN¥197.56 Million ▲ +13.0%
2010 1.90x CN¥86.71 Million CN¥164.81 Million ▲ +109.0%
2009 0.91x CN¥82.18 Million CN¥74.75 Million ▲ +58.7%
2007 0.57x CN¥31.85 Million CN¥18.26 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow